Eli Lilly Breaks Above €1,000 as CVS Caremark Complements Historic Obesity Data

Eli Lilly shares break €1,000 as CVS Caremark adds Zepbound, completing PBM coverage. Retatrutide shows 28.3% weight loss; Q1 revenue jumps 56%.

Eli Lilly has punched through a fresh psychological barrier, with shares climbing to €1,002.40 — a gain of 3.5% on the day — as the last piece of its US pharmacy-benefit coverage fell into place. The trigger: CVS Caremark agreed to include the injectable obesity drug Zepbound in its formulary from October, meaning all three major pharmacy-benefit managers now list Lilly’s metabolic portfolio. The move lifts the stock clear of its previous all-time high of €985 and reinforces the narrative of a company whose pipeline is delivering results across multiple fronts simultaneously.

Full PBM coverage eliminates a key access bottleneck

CVS Caremark had already included the oral GLP-1 pill Foundayo since early June. With Zepbound now on board, Lilly’s lineup is covered by Express Scripts, Optum Rx and CVS Caremark — the trio that controls the bulk of US prescription-drug access. For millions of insured patients, that means sharply lower out-of-pocket costs; for Lilly, it translates into a much larger addressable market and a smoother path to volume growth. The company now commands the clean sweep that analysts had identified as a critical near-term catalyst.

Retatrutide sets a new bar in weight-loss efficacy

Alongside the commercial breakthrough, clinical data released at the American Diabetes Association congress in New Orleans have given investors even more reason to stay bullish. The Phase 3 TRIUMPH-1 study of Retatrutide — a triple agonist targeting three hormone receptors — delivered an average weight reduction of 28.3% over 80 weeks. Nearly half the patients on the highest dose shed at least 30% of their body weight, a result previously achievable only through bariatric surgery. The trial did come with a caution: around 11% of participants in the top-dose arm discontinued because of side effects. Still, analysts described the efficacy as “unprecedented” and note that Lilly plans to submit the drug for regulatory clearance in the fourth quarter of 2026.

Foundayo goes head-to-head with Wegovy in the oral arena

Lilly’s oral GLP-1 candidate Foundayo, which received FDA approval in April, is already turning the metabolic market into a two-horse race. Novo Nordisk’s oral Wegovy variant has racked up more than 300,000 prescriptions this year, but Lilly is betting that its own Phase 3 data — which include a cardiovascular protective effect — will give doctors and patients a compelling reason to switch. Tablets lower the psychological barrier for those who avoid injections, and the cardioprotective signal could open the door to broader prescribing guidelines.

First-quarter results underscore the financial engine

The company’s momentum is not just clinical. For the first quarter of 2026, Eli Lilly reported revenue of $19.8 billion, a 56% jump year-on-year. Earnings per share came in at $8.55, well ahead of the consensus range of $6.80 to $7.00. The twin blockbusters Mounjaro and Zepbound contributed $8.66 billion and $4.16 billion, respectively. Management is guiding for full-year revenue of up to $85 billion, a target that looks increasingly attainable as PBM coverage expands and the oral drug gains traction.

A $12-billion M&A spree shifts the portfolio balance

Lilly has not been content to rest on its metabolic laurels. The company executed several large acquisitions in 2026, notably shelling out roughly $7.8 billion for Centessa Pharmaceuticals together with further deals for Curevo, Kelonia Therapeutics, and others — totalling nearly $12 billion. The aim is to diversify into vaccines, rare diseases, and oncology, reducing the reliance on the hugely profitable but increasingly competitive weight-loss market. The Centessa takeout alone signals a serious commitment to broadening the pipeline beyond GLP-1 and triple-agonist mechanisms.

Oncology emerges as an unexpected tailwind

On the ASCO stage, researchers from the University of Pennsylvania presented data from a real-world analysis of more than 111,000 women showing that GLP-1 users had roughly 30% lower incidence of breast cancer. Additional studies hint at slower progression of lung and liver cancers. While these are early observational findings, they could significantly expand the therapeutic indications for Lilly’s metabolic drugs and bolster prescriber confidence.

Analysts at Morgan Stanley have an "Overweight" rating and a price target of $1,344, while Bank of America sees the stock at $1,251, pointing to Lilly’s dominant position in metabolism. At a trailing P/E of roughly 29 — well above the sector average of 17 — the premium valuation is a clear reflection of the growth trajectory. With the share price now hovering just north of the all-time high, the next milestone — the trillion-dollar market cap — is within striking distance.